2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injection
2007
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2007, 120: 1146-1152. PMID: 17904628, PMCID: PMC3476046, DOI: 10.1016/j.jaci.2007.07.055.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Allergic AgentsAntibodies, Anti-IdiotypicAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAsthmaCost-Benefit AnalysisHumansModels, TheoreticalOmalizumabSeverity of Illness IndexConceptsQuality-adjusted life yearsCost-effectiveness ratioSevere asthmaEvent ratesSevere allergic asthmaQuality-adjusted monthsAllergic asthmaMost patientsAlternative medicationsHigher acquisition costUS FoodAsthmaDrug AdministrationLife yearsPatientsIncremental costDisease managementOmalizumabCost-effective optionTreatmentAcquisition costsEconomic outcomesCorticosteroidsMedicationsClinicians